TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06172036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan liposome + oxaliplatin + 5-FU / LV
Description: Efficacy and safety of irinotecan liposome combined with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin calcium (LV) with or without adbellizumab for resectable pancreatic cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan liposome + oxaliplatin + 5-FU / LV
Description: Efficacy and safety of irinotecan liposome combined with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin calcium (LV) with or without adbellizumab for resectable pancreatic cancer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan liposome + oxaliplatin + 5-FU / LV
Description: Efficacy and safety of irinotecan liposome combined with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin calcium (LV) with or without adbellizumab for resectable pancreatic cancer
Study: NCT05860166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Scale
Description: Developing an Neurodevelopment Test for evaluating infants in their neonatal period.
Study: NCT05080686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posthorax Thoraxbelt
Description: The patients will be assisted to put on the ThoraxBelt after surgery or at the emergency room by our research members and will be asked to keep it on except for showering through the whole study period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posthorax Thoraxbelt
Description: The patients will be assisted to put on the ThoraxBelt after surgery or at the emergency room by our research members and will be asked to keep it on except for showering through the whole study period.
Study: NCT05998876

Intervention type: DEVICE
Intervention: Remote Medication Monitor (RMM) - Prototype
Description: Inserted Microneedle Electrode Array for assaying dermal interstitial fluid.

Intervention type: DEVICE
Intervention: Remote Medication Monitor (RMM) - Prototype
Description: Inserted Microneedle Electrode Array for assaying dermal interstitial fluid.
Study: NCT05902481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: education about breastfeeding with mixed reality technology.
Study: NCT06038994

Intervention type: OTHER
Intervention: No intervention
Description: This is an obvertional study, and there is no intervention.
Study: NCT04152213

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Low GI diet
Description: This educational session will cover information on obesity, complications of obesity, the benefit of weight loss, the glycemic index and its associated low GI diet, a food-exchange table including high- to low-GI foods, and self-decision in food choices. The dietary advice will be based on the standard food pyramid for the conventional Chinese diet as promoted by the Hong Kong Department of Health, with an emphasis on the selection of low-GI products. Practical tips will be given such as the selection of low-GI rice and rice products, the impact of cooking methods (including cooking time, cooking conditions, and cooking liquid volume) on rice GI, intervention to reduce the GI of rice, and listing low-GI food options and meal plans.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low GI diet
Description: This educational session will cover information on obesity, complications of obesity, the benefit of weight loss, the glycemic index and its associated low GI diet, a food-exchange table including high- to low-GI foods, and self-decision in food choices. The dietary advice will be based on the standard food pyramid for the conventional Chinese diet as promoted by the Hong Kong Department of Health, with an emphasis on the selection of low-GI products. Practical tips will be given such as the selection of low-GI rice and rice products, the impact of cooking methods (including cooking time, cooking conditions, and cooking liquid volume) on rice GI, intervention to reduce the GI of rice, and listing low-GI food options and meal plans.
Study: NCT06507033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application and an arm volume measurement device
Description: The intervention consists mainly of two steps; (a) development of a mobile application with an arm volume measurement device (b) evaluation of the effectiveness of the products. Five components will be involved in the development of the mobile application. These components are; (I) exercise, (II) education, (III) coping mechanisms, (IV) arm volume measurement/recording and (V) appointment, exercise and measurement reminder panel. Exercise videos will include stretching exercises for the shoulder and arm as recommended in the guidelines
Study: NCT05001672

Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir alafenamide
Description: Tenofovir alafenamide (TAF, brand name: Vemlidy) is a hepatitis B virus nucleotide reverse transcriptase inhibitor oral medication for the treatment of chronic hepatitis B virus infection. It is a prodrug of tenofovir. Closely related to the commonly used reverse-transcriptase inhibitor tenofovir disoproxil fumarate, TAF has greater antiviral activity and better distribution into lymphoid tissues than that agent. Vemlidy was approved by the U.S. Food and Drug Administration (FDA) in November 2016 and the TAIWAN Food and Drug Administration (TFDA) in April 2017.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide
Description: Tenofovir alafenamide (TAF, brand name: Vemlidy) is a hepatitis B virus nucleotide reverse transcriptase inhibitor oral medication for the treatment of chronic hepatitis B virus infection. It is a prodrug of tenofovir. Closely related to the commonly used reverse-transcriptase inhibitor tenofovir disoproxil fumarate, TAF has greater antiviral activity and better distribution into lymphoid tissues than that agent. Vemlidy was approved by the U.S. Food and Drug Administration (FDA) in November 2016 and the TAIWAN Food and Drug Administration (TFDA) in April 2017.
Study: NCT05422027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Selinexor dose escalation: 40, 60mg respectively on day 1,8,15 for 21 days cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: The investigators gave patients subcutaneous bortezomib 1.3mg/sqm on days 1, 8,15 of a 21- day cycle.~standard bortezomib-lenalidomide-dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: The investigators gave patients oral lenalidomide 25mg on days 1 to 14 of a 21-day cycle.~standard bortezomib-lenalidomide-dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: The investigators gave patients oral dexamethasone 40mg on days 1, 8, 15 of a 21-day cycle.~standard bortezomib-lenalidomide-dexamethasone
Study: NCT04844970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anamorelin Hydrochloride
Description: Anamorelin HCl is an orally-active selective ghrelin receptor agonist which has shown anabolic and appetite-stimulating effects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Anamorelin placebo
Study: NCT05119140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 400mg of hydroxychloroquine per oral daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine
Description: the participant will maintain their current standard of care dose which can range from 1.5g to 4.8g of mesalamine per oral daily
Study: NCT06069973

Intervention type: OTHER
Intervention: No intervention, observational study
Description: No intervention

Intervention type: OTHER
Intervention: No intervention, observational study
Description: No intervention
Study: NCT06172036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebellizumab
Description: Efficacy and safety of irinotecan liposome combined with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin calcium (LV) with or without adbellizumab for resectable pancreatic cancer
Study: NCT05884567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercises
Description: These exercises are used to increase muscle endurance, power and ROM

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization
Description: These exercises are used to increase ROM and used for pain reduction
Study: NCT05642806

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab will be administered subcutaneously (SC) every 4 weeks for a total of 24 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously (SC) every 4 weeks for a total of 24 weeks
Study: NCT06134193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC
Description: hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil, leucovorin (FOLFOX) treatment (Q3W) Oxaliplatin: 85mg/m2 , Day 1 Leucovorin: 200mg/m2, Day 1 Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: 250mg PO d1, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg IV d1, Q3W
Study: NCT05770492

Intervention type: DIAGNOSTIC_TEST
Intervention: anterior segment optical coherence tomography
Description: Two different optical systems (MS-39, Costruzione Strumenti Oftalmici Italy; Anterion optical coherence tomographer, Heidelberg Engineering) will be used for acquisition of cross-sectional scans. Radial scan patterns will be used for acquisition.

Intervention type: DIAGNOSTIC_TEST
Intervention: anterior segment optical coherence tomography
Description: Two different optical systems (MS-39, Costruzione Strumenti Oftalmici Italy; Anterion optical coherence tomographer, Heidelberg Engineering) will be used for acquisition of cross-sectional scans. Radial scan patterns will be used for acquisition.
Study: NCT04891978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AIRQ
Description: A validated tool designed to identify patients who may be at risk for adverse outcomes from uncontrolled asthma.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma Checklist
Description: A validated, 3-page tool, based on GINA and NAEPP guidelines to assist providers with recognition, evaluation, and optimization of all patients with asthma. In this study, healthcare providers will be required to complete the assess component (page 1) of the Asthma Checklist .

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRECISION Program (Educational Resources)
Description: Educational resources accessible to all providers in the study. There are provider-facing and patient-facing educational materials that can be accessed during the patient visit or as resources for before/after visits. Resources can be downloaded and sent to patients per the discretion of providers.
Study: NCT05364515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRGF
Description: Plasma Rich in Growth Factors (PRGF) is a mixture of proteins and growth factors obtained from the blood of the patient.~Four PRGF infiltrations (two weeks between each infiltration). Then, application of topical PRGF serum (on alternate basis)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol Propionate
Description: 0.05 propionate clobetasol: daily (first month), alternate (second moth), twice per week (from third month)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol Propionate
Description: 0.05 propionate clobetasol: daily (first month), alternate (second moth), twice per week (from third month)
Study: NCT03941509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship
Description: Education, guidelines, communication tools and audit and feedback
Study: NCT05474326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent pneumatic pressure device (Kendall SCD™ 700 Smart Compression™ System)
Description: application of intermittent pneumatic pressure device (Kendall SCD™ 700 Smart Compression™ System) on lower limbs and its effect on fetal and maternal doppler and amniotic fluid index in women with oligohydramnios. the compression system will be applicated on lower limbs for one hour in which it will produce intermittent compression on lower limbs. amniotic fluid amnout assessment will be done after this including doppler studies in order to detect any change in amniotic fluid amount or dopper.
Study: NCT06182241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Retention in cervical cancer care intervention
Description: Aim 1 data will inform this intervention, however the participant intervention will likely be one or two sessions, conducted in-person, coupled with text- or phone-based client navigation with women who received abnormal high-risk Pap smear results. We anticipate that the intervention may integrate (1) information to improve awareness of cervical cancer susceptibility and treatment, (2) motivational interviewing to assess pros and cons of attending a follow-up appointment and completing treatment; (3) brief cognitive behavioral therapy (CBT) skills to reduce individual-level barriers, (4) problem-solving to increase social support, and (5) patient navigation tools to mitigate clinic-level challenges.
Study: NCT05818514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]AZ14132516
Description: Injection of radioligand for PET examinations
Study: NCT06308250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIME THERAPY
Description: Mime therapy consist of:~Self massage: patients will be taught to massage their face and neck daily for about 10 minutes which includes effleurage and kneading of both sides of face.~Breathing exercises: patient will be taught to recognize tension and feel the difference between tension and relaxation in facial musculature for 5 minutes. Expiration exercises will be used to induce relaxation.~Articulation: vowels such as a,e,i,o,u and consonants such as p and b will be used to teach position of the lips for 5 minutes.~Facial expression exercises: forehead wrinkle, smiling, eye closure, frowning, disgust, surprise, anger, sadness will be performed for 10 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACTION OBSERVATION THERAPY
Description: Function of each of the muscle is observed for 3 minutes and then executed for 2 minutes.~Frontalis (Raising eyebrows and forehead wrinkling). Corrugator Supercili (Moving the eyebrow down and inward toward the nose and inner eye).~Orbicularis oculi (Closing the eyelids). Buccinator (Blowing air in and out of the mouth). Zygomaticus major (Smiling). Orbicularis oris (Lip pursing or puckering).
Study: NCT06254976

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: 2 weeks of home exercise

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: intraarticular knee PRP injections
Description: 2 doses of intra-articular platelet rich plasma (PRP) injection, 1 week apart
Study: NCT06129981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imaginary exposure therapy augmented by vocal feedback
Description: The procedure specific to the study~* adding inclusion procedures (explanation of the study, verification of inclusion and non-inclusion criteria, signature of informed consent)~* including, in the usual initial V0 visit, psychometric measures specific to the study (RSDI, CGI, PMI, GEW)~* including a single usual psychotherapy session (i.e. not augmented) S1, during which the psychometric (RSDI, PMI, GEW) and psychophysiological (connected watch) measurements specific to the study are used~* adding the VF device and using psychometric (RSDI, PMI, GEW) and psychophysiological (connected watch) measurements specific to the study during psychotherapy sessions S2 to Sn (minimum S6)~* adding, during the last usual end-of-treatment visit, psychometric measures specific to the study (CGI)~* adding psychometric measures specific to the study during the usual follow-up visit at 3 months~* adding a follow-up visit at 12 months (CGI, PCL-5), either by telephone or on-site.
Study: NCT06196164

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-BD
Description: We observe the bile duct through endoscopic ultrasound, then puncture through the gastric or duodenum wall and place a guide wire, expanding along the guide wire, finally place a stent between the bile duct and the stomach or intestine for drainage.
Study: NCT05998876

Intervention type: DEVICE
Intervention: Remote Medication Monitor (RMM) - Prototype
Description: Inserted Microneedle Electrode Array for assaying dermal interstitial fluid.

Intervention type: DRUG
Intervention: Daily Methadone Dose
Description: patient takes their prescribed daily dose of methadone

Intervention type: DRUG
Intervention: Daily Methadone Dose
Description: patient takes their prescribed daily dose of methadone

Intervention type: DRUG
Intervention: Daily Methadone Dose
Description: patient takes their prescribed daily dose of methadone
Study: NCT03446807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: Droxidopa in 100, 200, and 300mg capsules. Maximum dose to be used in this study is 600mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo capsules to match Droxidopa 100, 200, and 300mg capsules.
Study: NCT05156268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously (IV) at 200mg every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib will be administered orally at 300 mg every 12 hours.
Study: NCT05665790

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: palliative surgery
Description: palliative surgery
Study: NCT06196164

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ERCP-BD
Description: We use a Duodenoscopy to pass through mouth down to the small opening where the bile duct and pancreatic drain. A small narrow catheter is passed through the scope to gain access to the drainage duct , followed by advancement of a wire deep into the duct. A small cut is made at the bile duct opening to help facilitate a stent placed in the bile duct.
Study: NCT05998135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paracentesis
Description: Undergo paracentesis
Study: NCT05726890

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: bedtime intervention for early childhood insomnia
Description: The intervention focuses on providing parents with skills on how to modify and limit their sleep-related interactions with their infant at bedtime. These changes are expected to foster the infant's ability to fall asleep independently at bedtime. It is also expected that after 1-2 weeks, these changes would lead to self-soothing also during the night.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: bedtime and nighttime intervention for early childhood insomnia
Description: The intervention focuses on providing parents with skills on how to modify and limit their sleep-related interactions with their infant at bedtime and during the night. These changes are expected to foster the infant's ability to fall asleep independently at bedtime and to resume sleep independently during the night.
Study: NCT05108805

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemedicine Visit
Description: A remote telemedicine visit with audio and video, using the internet with a nurse practitioner located elsewhere. The participant and NP will activate the telemedicine App in their electronic device. Family will obtain vital signs (BP, HR, RR, SPO2) and provide NP with the information. NP will also review the previous vital signs. Review of system questions are asked, and the answers given by subject recorded. Neurological assessment done, and ICE score calculated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vital sign measurements
Description: Participant and their family will record and measure vital signs using a wearable device and will place a call to the covering nurse practitioner to report the vital signs prior to reporting to the out patient visit.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Out-Patient Clinic Visit
Description: Physical exam and review of all available data

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood pressure and pulse oximeter
Description: Participant and their family take their blood pressure and pulse oximeter
Study: NCT04358159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventralex
Description: Repair of the hernia by a Ventralex patch in sublay position

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Progrip
Description: Repair of the hernia by a Progrip mesh in onlay position
Study: NCT03322813

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate 4000 - Type 2
Description: Using ExAblate Model 4000 Type-2 to temporarily disrupt the blood brain barrier in non-enhancing suspected infiltrating glioma undergoing resection
Study: NCT05378295

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fermentable oligosaccharide
Description: Supplementation period 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Personalized fiber mixture
Description: Supplementation period 12 weeks
Study: NCT05949528

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT06303362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic band excercise
Description: experimenatal group was given elastic band excercises along with stretching (pectoralis major, minor, trapezius, rhomboids and neck flexors) and conventional therapy. Sessions will be given 3 days in a week for a period of 4 weeks. The assessment was done at baseline, after 2 weeks and at the end of 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: strengthening with conventional physical therapy
Description: control group was given strengthening excercises and stretching (pectoralis major, minor, trapezius, rhomboids (Sessions will be given 3 days in a week for a period of 4 weeks. The assessment was done at baseline, after 2 weeks and at the end of 4 weeks.